中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
12期
1295-1298
,共4页
2型糖尿病%二甲双胍%西格列汀%吡格列酮%血糖
2型糖尿病%二甲雙胍%西格列汀%吡格列酮%血糖
2형당뇨병%이갑쌍고%서격렬정%필격렬동%혈당
Type 2 diabetes mellitus%Metformin%Sitagliptin%Pioglitazone%Blood glucose level
目的 观察并分析二甲双胍分别联合西格列汀、吡格列酮治疗2型糖尿病(T2DM)的临床效果及安全性.方法 将2011年1月至2012年12月我院收治的76例T2DM患者随机分为A(n =40)、B(n =36)两组,A组患者予二甲双胍+西格列汀方案,B组予二甲双胍+吡格列酮方案,疗程12周.12周后对比两组患者血糖浓度、临床疗效及药物不良反应.结果 (1)服药12周后,A、B两组空腹血糖[(6.4±1.8)、(7.0±1.9) mmol/L]、餐后2h血糖[(8.1±2.7)、(9.5 ±2.8)mmol/L]及糖化血红蛋白[(6.2±2.1)％、(7.1±2.2)％]均较治疗前明显下降[(9.4±2.4)、(9.1±2.5) mmol/L与(13.6±4.5)、(13.3±4.9) mmol/L与(9.2±2.4)％、(8.9±2.6)％,t值分别为6.325、4.013、6.628、4.040、5.950、3.171,P均＜0.05].A组患者餐后2h血糖浓度(8.1±2.7) mmol/L明显低于B组(9.5±2.8)mmol/L(t =2.214,P=0.030).(2)A组患者总有效率90.0％ (36/40)略高于B组83.3％(30/36),差异无有统计学意义(x2=0.269,P=0.604).(3)A、B两组用药期间分别发生药物不良反应10例(25.0％)、11例(30.6％),两组不良反应发生率比较差异无统计学意义(x2=0.292,P=0.589).结论 二甲双胍分别联合西格列汀、吡格列酮方案均是治疗T2DM的有效方案,前者临床效果具有优势,尤其是对降低餐后血糖优势明显.
目的 觀察併分析二甲雙胍分彆聯閤西格列汀、吡格列酮治療2型糖尿病(T2DM)的臨床效果及安全性.方法 將2011年1月至2012年12月我院收治的76例T2DM患者隨機分為A(n =40)、B(n =36)兩組,A組患者予二甲雙胍+西格列汀方案,B組予二甲雙胍+吡格列酮方案,療程12週.12週後對比兩組患者血糖濃度、臨床療效及藥物不良反應.結果 (1)服藥12週後,A、B兩組空腹血糖[(6.4±1.8)、(7.0±1.9) mmol/L]、餐後2h血糖[(8.1±2.7)、(9.5 ±2.8)mmol/L]及糖化血紅蛋白[(6.2±2.1)％、(7.1±2.2)％]均較治療前明顯下降[(9.4±2.4)、(9.1±2.5) mmol/L與(13.6±4.5)、(13.3±4.9) mmol/L與(9.2±2.4)％、(8.9±2.6)％,t值分彆為6.325、4.013、6.628、4.040、5.950、3.171,P均＜0.05].A組患者餐後2h血糖濃度(8.1±2.7) mmol/L明顯低于B組(9.5±2.8)mmol/L(t =2.214,P=0.030).(2)A組患者總有效率90.0％ (36/40)略高于B組83.3％(30/36),差異無有統計學意義(x2=0.269,P=0.604).(3)A、B兩組用藥期間分彆髮生藥物不良反應10例(25.0％)、11例(30.6％),兩組不良反應髮生率比較差異無統計學意義(x2=0.292,P=0.589).結論 二甲雙胍分彆聯閤西格列汀、吡格列酮方案均是治療T2DM的有效方案,前者臨床效果具有優勢,尤其是對降低餐後血糖優勢明顯.
목적 관찰병분석이갑쌍고분별연합서격렬정、필격렬동치료2형당뇨병(T2DM)적림상효과급안전성.방법 장2011년1월지2012년12월아원수치적76례T2DM환자수궤분위A(n =40)、B(n =36)량조,A조환자여이갑쌍고+서격렬정방안,B조여이갑쌍고+필격렬동방안,료정12주.12주후대비량조환자혈당농도、림상료효급약물불량반응.결과 (1)복약12주후,A、B량조공복혈당[(6.4±1.8)、(7.0±1.9) mmol/L]、찬후2h혈당[(8.1±2.7)、(9.5 ±2.8)mmol/L]급당화혈홍단백[(6.2±2.1)％、(7.1±2.2)％]균교치료전명현하강[(9.4±2.4)、(9.1±2.5) mmol/L여(13.6±4.5)、(13.3±4.9) mmol/L여(9.2±2.4)％、(8.9±2.6)％,t치분별위6.325、4.013、6.628、4.040、5.950、3.171,P균＜0.05].A조환자찬후2h혈당농도(8.1±2.7) mmol/L명현저우B조(9.5±2.8)mmol/L(t =2.214,P=0.030).(2)A조환자총유효솔90.0％ (36/40)략고우B조83.3％(30/36),차이무유통계학의의(x2=0.269,P=0.604).(3)A、B량조용약기간분별발생약물불량반응10례(25.0％)、11례(30.6％),량조불량반응발생솔비교차이무통계학의의(x2=0.292,P=0.589).결론 이갑쌍고분별연합서격렬정、필격렬동방안균시치료T2DM적유효방안,전자림상효과구유우세,우기시대강저찬후혈당우세명현.
Objective To investigate clinical efficacy and safety of metformin combined with sitagliptin or pioglitazone in treatment of type 2 diabetes mellitus (T2DM).Methods Senvnty-six patients with T2DM hospitalized from January 2011 to December 2012 were randomly divided into A(n =40) and B (n =36) group.Patients in group A were given metformin plus sitagliptin scheme for 12 weeks,and in group B were given metformin plus pioglitazone scheme for 12 weeks.The blood glucose level was measured and clinical efficacy and adverse drug reactions during treatment were record.Results (1) Fasting plasma glucose (FPG),2 h postprandial blood glucose(2 hPBG) and glycosylated hemoglobin(GH) in A and B group after 12 weeks of treatment were (6.4 ± 1.8) mmol/L,(7.0 ± 1.9) mmol/L; (8.1 ± 2.7) mmol/L,(9.5 ± 2.8) mmol/L; (6.2 ± 2.1) ％,(7.1 ± 2.2) ％,lower than that of pre-treatment ((9.4 ± 2.4) mmol/L,(9.1 ± 2.5) mmol/L; (13.6 ± 4.5) mmol/L,(13.3 ± 4.9) mmol/L; (9.2 ± 2.4) ％,(8.9 ± 2.6) ％ and the difference were significant (t =6.325,4.013,6.628,4.040,5.950,3.171 respectively,P ＜ 0.05).2 hPBG level of group A was (8.1 ±2.7) mmol/L,lower than that of group B ((9.5 ±2.8) mmol/L,t =2.214,P =0.030).(2) Efficiency in group A was 90.0％ (36/40),slightly higher than that of group B (83.3％ (30/36)),but the difference was not statistically significance (x2 =0.269,P =0.604).(3) There were no seriously adverse drug reactions in two groups.Rates of adverse reactions in two groups were 25.0％ (10 cases),30.6％ (11 cases) respectively (x2 =0.292,P =0.589).Conclusion Both treatment plans were proved effective in treatment of patients with T2DM.Compared with plan of metformin plus pioglitazone,metformin plus sitagliptin was showed a comparative advantage in clinical efficacy,especially with outstanding curative effect in reducing postprandial blood glucose.
